ICOSAPENT ETHYL

Post-LOE

icosapent ethyl

Inpharmus

ANDAORALCAPSULE

Approved

Sep 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ICOSAPENT ETHYL (icosapent ethyl) by Inpharmus is low-density lipoprotein triglycerides (vldl-tg) synthesis and/or secretion and enhances tg clearance from circulating vldl particles. First approved in 2023.

Drug data last refreshed 20h ago

$0.1BPart D

Mechanism of Action

low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver;…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (3)

NCT04562467Phase 4Completed

The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

Started Sep 2020

70 enrolled

Cardiovascular DiseasesCardiovascular Risk FactorTriglycerides High+1 more

NCT04505098Phase 4Terminated

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Started Aug 2020

39,600 enrolled

Covid19AtherosclerosisCardiovascular Diseases+1 more

NCT04412018Phase 2Completed

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

Started Jun 2020

100 enrolled

COVID-19Inflammatory Response

Worked on ICOSAPENT ETHYL at Inpharmus? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.